Rituximab as Second Line Treatment for ITP; A Multicenter, Randomized, Double Blind, Placebo-controlled, Phase III Study. "The RITP Study"
Phase of Trial: Phase III
Latest Information Update: 05 Aug 2019
Price : $35 *
At a glance
- Drugs Rituximab (Primary)
- Indications Idiopathic thrombocytopenic purpura; Thrombocytopenia
- Focus Therapeutic Use
- Acronyms RITP
- 16 Dec 2013 New trial record
- 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
- 09 Dec 2013 Primary endpoint 'Treatment-failure-rate' has not been met.